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CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Elevated MMP-12 protein levels in induced sputum
from patients with COPD
I K Demedts, A Morel-Montero, S Lebecque, Y Pacheco, D Cataldo, G F Joos,
R A Pauwels, G G Brusselle
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See end of article for
authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . .
Correspondence to:













. . . . . . . . . . . . . . . . . . . . . . .
Thorax 2006;61:196–201. doi: 10.1136/thx.2005.042432
Background: Several matrix metalloproteinases (MMPs) are involved in the pathogenesis of chronic
obstructive pulmonary disease (COPD). In mice, MMP-12 plays a crucial role in the development of
cigarette smoke induced emphysema. A study was undertaken to investigate the role of MMP-12 in the
development of COPD in human smokers.
Methods: Induced sputum samples were collected from patients with stable COPD (n = 28), healthy
smokers (n = 14), never smokers (n = 20), and former smokers (n = 14). MMP-12 protein levels in induced
sputum were determined by ELISA and compared between the four study groups. MMP-12 enzymatic
activity in induced sputum was evaluated by casein zymography and by cleaving of a fluorescence
quenched substrate.
Results: Median (IQR) MMP-12 levels were significantly higher in COPD patients than in healthy smokers,
never smokers, and former smokers (17.5 (7.1–42.1) v 6.7 (3.9–10.4) v 4.2 (2.4–11.3) v 6.1 (4.5–
7.6) ng/ml, p = 0.0002). MMP-12 enzymatic activity was significantly higher in patients with COPD than
in controls (4.11 (1.4–8.0) v 0.14 (0.1–0.2) mg/ml, p = 0.0002).
Conclusion: MMP-12 is markedly increased in induced sputum from patients with stable COPD compared
with controls, suggesting a role for MMP-12 in the development of COPD in smokers.
C
hronic obstructive pulmonary disease (COPD) is a
major health problem and it is predicted that it will
be the third most common cause of death worldwide by
2020.1 The disease is mainly caused by cigarette smoking
which leads to chronic inflammation of the airways and
parenchymal destruction resulting in emphysema. The
destruction of lung tissue is caused by an imbalance between
protease and antiprotease activity, where the excess of
proteolytic enzymes such as matrix metalloproteinases
(MMPs), cysteine, and serine proteinases is insufficiently
counterbalanced by a rise in antiproteolytic molecules.2
Matrix metalloproteinases are a family of metalloproteases
that contain a zinc atom at their active site and are able to
degrade matrix macromolecules including collagen, laminin,
and elastin.3 In addition to their ability to degrade extra-
cellular matrix components, some MMPs also cleave cyto-
kines4 and antiproteolytic molecules.5–7
An understanding of the functional activity of MMPs and
the fact that MMPs such as MMP-9 and MMP-12 were found
in alveolar macrophages8 9 led to the hypothesis that these
enzymes could play a role in the destruction of lung
parenchyma induced by cigarette smoke. More specifically,
there is convincing evidence from animal models that MMP-
12 is crucial in the development of smoke induced
emphysema. MMP-12 knock out mice were completely
protected from development of emphysema despite long
term smoke exposure, while wild type mice developed
alveolar space enlargement.10 In addition, MMP-12 knock
out mice had impaired recruitment of monocytes into the
lung, possibly due to the loss of MMP-12 mediated
generation of elastin fragments (chemotactic for monocytes).
The contribution of MMP-12 to smoke induced emphy-
sema is probably not limited to a direct effect (destruction of
extracellular matrix) but is almost certainly enhanced by
indirect effects such as inactivation of a1-antitrypsin by
MMP-1211 and MMP-12 mediated recruitment of neutrophils
(which in their turn are able to release proteolytic enzymes)
to the lung in response to cigarette smoke.4
Altogether, these data suggest a pivotal role for MMP-12 in
the development of smoke induced emphysema in mice.
However, in human subjects the role of MMP-12 in the
development of COPD is still unclear. Very few studies have
investigated the involvement of MMP-12 in cigarette smoke
induced lung damage in human subjects, partly because of
the lack of appropriate diagnostic tools to detect the MMP-12
protein in sputum, bronchoalveolar lavage (BAL) fluid or
lung tissue. One group found an association between
polymorphisms in the MMP-12 gene and the rate of decline
of lung function in smokers, which suggests a role for MMP-
12 in the pathogenesis of COPD.12 Molet and colleagues
recently reported increased MMP-12 levels in BAL fluid
(demonstrated by Western blot analysis), BAL cells, and
bronchial biopsy tissue from COPD patients compared with
controls.13
To explore the contribution of MMP-12 to the development
of COPD in smokers, induced sputum samples were collected
from never smokers, healthy smokers (smokers without
airway obstruction), former smokers (quit smoking for more
than 1 year), and patients with stable COPD and the MMP-
12 levels in the induced sputum samples in the four groups
were compared.
Abbreviations: BAL, bronchoalveolar lavage; COPD, chronic
obstructive pulmonary disease; DTT, dithiotreitol; ECM, extracellular
matrix; ELISA, enzyme linked immunosorbent assay; FEV1, forced
expiratory volume in 1 second; FVC, forced vital capacity; GOLD,
Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled
corticosteroids; IFN-c, interferon-c; IL-13, interleukin-13; MMP, matrix
metalloproteinase; PBS, phosphate buffered saline; TGF-b1,
transforming growth factor b1; TNF-a, tumour necrosis factor a
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METHODS
Subjects
Seventy six subjects participated in the study and were
classified in four groups: COPD stage I (mild) to II
(moderate) patients according to the GOLD (Global
Initiative for Chronic Obstructive Lung Disease) criteria
(www.goldcopd.com), never smokers, healthy smokers, and
former smokers (subjects who quit smoking for more than a
year with a smoking history of at least 10 pack years).
Patients were recruited from our outpatient pulmonary clinic
while controls were recruited by advertising as well as from
the outpatient clinic. All patients with COPD had stable
disease; patients with symptoms or clinical signs of a COPD
exacerbation in the preceding 2 months were excluded. For
safety reasons, patients suffering from severe and very severe
COPD (GOLD stage III–IV) were excluded, as were subjects
with asthma, bronchiectasis, or a respiratory infection in the
preceding 4 weeks. Written informed consent was obtained
from all subjects according to protocols approved by the
medical ethical committee of the Ghent University Hospital.
Sputum induction and processing
Sputum induction was performed as described previously14 by
inhalation of sterile, pyrogen-free, hypertonic saline at
increasing concentrations (NaCl 3%, 4%, and 5%, respec-
tively) over a 5 minute period after the inhalation of
salbutamol (26200 mg). The hypertonic saline was nebulised
via an ultrasonic nebuliser (Ultra-Neb; Devilbiss Health Care
Inc, Somerset, PA, USA). Each time after the inhalation of a
specific saline concentration, subjects were encouraged to
cough and expectorate an adequate sample. Spirometric
values were obtained before and after induction by means of
a water sealed spirometer (Vmax 20C, Sensormedics, Yorba
Linda, CA, USA). Processing of induced sputum was
performed as previously described.15 To reduce salivary
contamination, sputum plugs were selected and transferred
in a polystyrene tube. A freshly prepared 0.1% solution of
dithiotreitol (DTT; 10% Sputalysin, Boehringer-Calbiochem
Corp, San Diego, CA, USA) was added in an amount equal to
four times the weight of the sputum plugs. The tube was
vortex mixed for 30 seconds and the sputum was incubated
on a tube rocker for 15 minutes at room temperature. An
amount of phosphate buffered saline (PBS) equal to the DTT
volume was then added and the sample was incubated for a
further 5 minutes. The sample was filtered through a 70 mm
cell strainer (Becton Dickinson Labware, NJ, USA) and
centrifuged at 390 g for 10 minutes. The supernatant was
aspirated, aliquoted, and stored at 280 C˚. The cell pellet was
resuspended in PBS supplemented with 2% human serum
albumin (Behring Diagnostics, San Jose, CA, USA); cells were
counted in a haemocytometer and the cell concentration was
adjusted to 0.76106 cells/ml. Cytospins were prepared by
adding 60 ml of cell suspension into Shandon II cytocen-
trifuge cups (Shandon Southern Instruments, Sewickley, PA,
USA) and spun for 5 minutes at 300 rpm. Two slides were
stained with May-Gru¨nwald-Giemsa for an overall count of
leucocytes, bronchial epithelial cells, and squamous cells.
Slides were counted blind by two investigators. For cell
differentiation, 400 nucleated cells per slide were counted
and expressed as the percentage of intact round nucleated
cells, excluding squamous epithelial cells.
Generation of antibodies against MMP-12
MMP-12 protein was detected in induced sputum super-
natant using an enzyme linked immunosorbent assay
developed in cooperation with industrial partners
(Immunotech, Marseille, France and Schering-Plough LIR,
Dardilly, France). Antibodies were generated as follows: the
full length MMP-12 cDNA was cloned from a cDNA library
constructed from CD34-derived dendritic cells. The clone was
entirely sequenced and shown to correspond to the published
sequence.9 The MMP-12 cDNA was cloned in PME18S vector
that was electroporated in COS7 cells. Enriched supernatant
was used to immunise Balb/C mice. Hybridomas (n = 23)
were obtained as previously described16 and screened by
immunostaining of COS7 transfected cells. Their specificity
was confirmed by Western blot analysis and by immunopre-
cipitation of radiolabelled recombinant MMP-12 (fig 1).
Development of ELISA for MMP-12 detection
Selection for ELISA was performed by testing the 23
antibodies obtained. The most sensitive ELISA used antibody
701E4.03 for capture and antibody 706F9.01 for detection of
MMP-12. Recombinant MMP-12 was immunopurified with a
third antibody, 603.E6.
Recombinant human MMP-12 with known concentrations
was used as standard. MMP-12 in sputum supernatant was
quantified by converting the optical density values of the
samples to nanograms from the standard curve obtained with
recombinant MMP-12. Sensitivity of the ELISA was less than
50 pg/ml. Specificity testing showed that there was no
detection of other related MMPs (fig 2) including MMP-1,
MMP-3 and MMP-9 (R&D Systems, Abingdon, UK) with the
ELISA for MMP-12 (kindly provided by Immunotech). Mean
intrabatch coefficient of variation of the ELISA was less than
6%.
54 kDa
1 2 3 4
Figure 1 Autoradiography of SDS gel electrophoresis without (lane 1)
or with (lane 2) b-mercaptoethanol of MMP12-transfected COS7 cells
supernatant radiolabelled with 35S. Immunoprecipitation of COS7
supernatant with monoclonal antibodies 701E4.03 (lane 3) and
706F9.01 (lane 4).
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Figure 2 Specificity of the ELISA for MMP-12. Detection of a serial
dilution of recombinant MMP-12 protein by the ELISA (&). No
recombinant MMP-1 (n), MMP-3 (,), or MMP-9 (%) were detected with
the ELISA, even at high concentrations.
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Since the use of dithiotreitol (DTT) in sputum processing
could possibly interfere with the detection of MMP-12 in
sputum samples, we compared MMP-12 levels in sputum
samples treated or untreated with DTT. Sputum samples were
divided into two aliquots: one aliquot was treated with DTT
(concentration matching the concentration used in the
standard procedure as described above), while PBS was
added to the other aliquot instead of DTT. Both samples were
then centrifuged (50 000 g, 4 C˚, 90 minutes) in an ultracen-
trifuge (Ultracentrifuge Floor Model L5-65, Beckman Coulter,
Fullerton, CA, USA) and sputum supernatant was stored at
280 C˚. The levels of MMP-12 measured by the ELISA were
compared between the two aliquots. There was no difference
in MMP-12 levels between these two methods (n = 13,
p = 0.89). Moreover, there was a strong positive correlation
(rs = 0.99; p = 0.000001) between MMP-12 levels in both
aliquots from the same sample (fig 3), so we concluded that
DTT has no influence on the detection of MMP-12 in sputum
samples.
Zymography
Casein zymography was performed based on a previously
described technique with slight modifications.17 Ten ml of
sputum supernatant were mixed with the same amount of
non-reducing sample buffer. Electrophoresis was carried out
on a sodium dodecyl sulfate (SDS)-10% polyacrylamide gel
containing a-casein (Sigma) at a concentration of 1 mg/ml.
Gels were then incubated in 2.5% (v/v) Triton X-100 for
30 minutes and soaked for 16 hours in a buffer containing
10 mM CaCl2 and 100 mM NaCl at 37 C˚. The gels were then
stained with Coomassie brillant blue G250. Caseinolytic
activity was detected as white lysis zones against a blue
background. Quantitative evaluation of the gelatinolytic
activity was performed by scanning the gel using a Bio-Rad
MultiImager imaging densitometer. Recombinant MMP-12
(R&D Systems, Abingdon, UK) was used to confirm the
validity of the procedure and bands obtained with rMMP-12
were used as standards. Caseinolytic activity was determined
by scanning the lysis band in the area corresponding to
rMMP-12.
MMP-12 activity assessed by fluorescence quenched
substrate cleaving
In addition to casein zymography, MMP-12 specific enzy-
matic activity was analysed using a technique based on the
EnzoLyte 490 kit (AnaSpec, San Jose, CA, USA) which was
slightly modified. This kit is optimised to detect the activity of
MMP-12 in biological samples using a fluorescence quenched
substrate (EDANS/DabcylPlusTM FRET peptide). Upon
cleavage into two separate fragments by MMPs, the
fluorescence of this peptide is recovered and can be
monitored at excitation/emission wavelengths of 340 nm/
490 nm. Sputum samples were incubated with 1 mM 4-
aminophenylmercuric acetate (APMA) for 1 hour to activate
MMP-12. 50 ml of the sample were incubated in a 96 well
plate. The plate was incubated at room temperature for
45 minutes and protected from light. Stop solution from
Anaspec (50 ml) was added to each well and the fluorescence
intensity was measured at 490 nm after excitation at 340 nm.
MMP-12 purified enzyme used as positive control was
purchased from Sigma (St Louis, Missouri, USA).
Analysis of data
Statistical analysis was performed with SPSS Version 12.0 for
Windows. Data are presented as median (IQR) and statistical
analysis was performed using non-parametric testing with
Kruskal-Wallis tests. Significant differences between groups
were further investigated by Mann-Whitney U testing.
Spearman’s rank correlation was calculated to assess the
correlation between MMP-12 levels, lung function para-
meters, and cell differential counts in induced sputum of
study subjects. Statistical significance was defined as p,0.05.
RESULTS
Subject characteristics
Twenty eight patients with stable COPD (no exacerbation in
the preceding 2 months) were included in the study (table 1).
Four were classified as COPD GOLD stage I while 24 had a
disease severity of GOLD stage II. Seventeen of the COPD
patients took inhaled steroids and 11 did not; 14 were active
smokers and 14 had quit smoking for more than 1 year.
Twenty never smokers, 14 healthy smokers, and 14 former
smokers were studied in the control groups. All healthy
subjects had normal spirometric values. The characteristics of
the four study groups are summarised in table 1. Forced
expiratory volume in 1 second (FEV1) and the FEV1/FVC
ratio were significantly lower in patients with COPD than in
the control groups.
Differential cell counts of induced sputum
Total and differential cell counts of induced sputum are
shown in table 2. The total inflammatory cell number in
induced sputum was significantly higher in patients with
COPD than in smokers without airway obstruction. The
percentage of macrophages was lower in the sputum of COPD
patients than in never smokers and active smokers, while
absolute numbers of macrophages in induced sputum were
not significantly different between the groups. Induced
sputum from COPD patients contained significantly more
neutrophils than induced sputum from never smokers and
active smokers (table 2).
MMP-12 protein in induced sputum
MMP-12 protein could be detected by ELISA in all induced
sputum samples (fig 4). Patients with COPD had significantly
higher levels of MMP-12 in induced sputum (median
17.5 ng/ml (IQR 7.1–42.1)) than never smokers (4.2 ng/ml
(2.4–11.3)), ‘‘healthy’’ smokers (6.7 ng/ml (3.9–10.4)), and
former smokers (6.1 ng/ml (4.5–7.6)). There was no sig-
nificant difference in MMP-12 levels between the three
control groups. MMP-12 levels in induced sputum from
COPD patients who were active smokers (16.1 ng/ml (5.8–
47.2)) did not differ significantly from those in COPD
patients who had quit smoking (18.2 ng/ml (10.1–38.9),
p = 0.87). There was no difference in the level of MMP-12
protein in sputum from COPD patients who were taking
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Figure 3 Effect of dithiotreitol (DTT) on the detection of MMP-12 in
sputum. Aliquots from the same sputum sample were processed with or
without DTT. There was a strong positive correlation (rs = 0.99;
p = 0.000001) between the MMP-12 levels in aliquots treated with DTT
and the corresponding aliquots processed without DTT. DTT therefore
has no effect on the detection of MMP-12 in sputum samples.
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who were not on inhaled corticosteroids (25.8 ng/ml (15.4–
72.8), p = 0.21).
Zymography
To evaluate MMP-12 enzymatic activity, a number of sputum
supernatants samples were analysed by casein zymography
(seven patients with COPD, five healthy smokers). As shown
in fig 5A, functionally active MMP-12 could be detected in
most samples from COPD patients but not in samples from
healthy smokers. The relative degree of enzymatic activity
was calculated as described above (fig 5B). There was a
strong positive correlation between the amount of MMP-12
detected by the ELISA and the degree of enzymatic activity as
evaluated by casein zymography (rs = 0.9; p = 0.01).
MMP-12 activity assessed by fluorescence quenched
substrate cleaving
In addition to casein zymography, MMP-12 specific enzy-
matic activity was analysed by cleavage of a fluorescence
quenched substrate. For this purpose, 10 samples from COPD
patients were analysed and compared with 10 control
samples (five smokers, three never smokers, and two former
smokers). MMP-12 specific activity was significantly higher
in COPD patients than in controls (4.11 (1.4–8.0) v 0.14 (0.1–
0.2) mg/ml, p = 0.0002). There was a strong positive correla-
tion between the degree of MMP-12 enzymatic activity and
the amount of MMP-12 detected by the ELISA (rs = 0.79;
p = 0.00002).
Correlations between sputum MMP-12 and clinical
and inflammatory parameters
An inverse correlation was found between MMP-12 protein
levels in induced sputum and the FEV1/FVC ratio (rs =20.44,
p = 0.00007) as well as the degree of airway obstruction
(rs =20.38, p = 0.0008) as measured by FEV1% when
analysed for all subjects (fig 6). However, when correlation
analysis was performed in each group separately, no
significant correlations were found between MMP-12 protein
levels and spirometric measurements. This suggests that the
observed correlation resulted from the differences between
the groups rather than representing a true association.
There was no correlation between MMP-12 levels and the
absolute number of macrophages, lymphocytes or eosino-
phils, while there was a positive correlation between MMP-12
and the absolute neutrophil counts (rs = 0.41, p = 0.0004) in
induced sputum when analysed for all subjects (fig 7).
However, when each group was analysed separately, a
significant correlation between the MMP-12 protein level
and absolute neutrophil number was found only in never
smokers (rs = 0.64, p = 0.002).
DISCUSSION
This is the first study to report detection of MMP-12 at the
protein level in induced sputum. Although several studies in
animal models have suggested a possible role for MMP-12 in
the development of COPD, very few data are available on the
role of MMP-12 in human lung diseases, mainly because of
the lack of appropriate diagnostic tools.
The major finding of this study was that the level of MMP-
12 in induced sputum was significantly higher in patients
with mild to moderate COPD than in the control groups
(never smokers, former smokers, and ‘‘healthy’’ smokers).
These findings suggest that MMP-12 is involved (together
with other proteolytic enzymes) in the development of COPD
and confirms earlier findings from animal models.10
An interesting finding was the difference in the MMP-12
level in induced sputum from patients with COPD and
‘‘healthy’’ smokers; MMP-12 levels were clearly increased in
COPD patients but not in smokers without airway obstruc-
tion. It therefore appears that MMP-12 is not induced in all
smokers but only in those with COPD.









Sex ratio (M/F) 24/4 4/16 7/7 7/7
Age (years) 64.0 (52–72)*` 52.5 (42–56) 51.0 (49–53) 52.5 (46–63)
Smoking history (pack years) 42.0 (26–55)`1 0.0 (0–0) 35.0 (16–43) 30.0 (9–42)
FEV1 (l) 2.0 (1.7–2.3) 3.0 (2.7–3.4) 3.0 (2.5–3.3) 3.4 (2.7–3.7)
FEV1 (% predicted) 70.0 (63–78) 105.5 (97–118) 96.0 (91–101) 108.0 (100–113)
FEV1/FVC (%) 56.0 (49–65) 80.5 (77–83) 78.0 (73–82) 78.5 (75–80)
Bronchodilators (Y/N) 20/8 0/20 0/14 0/14
ICS (Y/N) 17/11 0/20 0/14 0/14
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroids.
Data are presented as median (IQR).
*p,0.01 v never smokers; p,0.001 v smokers; `p,0.05 v former smokers; 1p,0.001 v never smokers; p,0.001 v never smokers, smokers and former
smokers.









Total inflammatory cells (6103/mg) 14.0 (8–21)* 6.5 (5–15) 5.6 (4–8) 10.8 (8–18)*
Macrophages (%) 34.8 (18–43)* 50.4 (38–68)` 52.3 (30–66) 36.6 (24–52)
Macrophages (6103/mg) 4.0 (2.1–6.4) 3.9 (2.9–5.1) 2.3 (1.8–3.5) 4.2 (2.6–5.6)
Neutrophils (%) 61.5 (56–75)* 48.0 (27–59)` 46.1 (32–66) 61.1 (47–75)
Neutrophils (6103/mg) 9.1 (4.5–15.0)1 3.3 (1.0–9.8) 2.3 (1.5–4.5)` 6.3 (3.9–13.0)
Eosinophils (%) 1.5 (0.5–3.1) 0.2 (0.0–0.7) 1.0 (0.6–1.6) 0.5 (0.0–1.8)
Eosinophils (6103/mg) 0.1 (0.0–0.6) 0.0 (0.0–0.1)* 0.1 (0.0–0.1) 0.1 (0.0–0.1)
Lymphocytes (%) 0.5 (0.2–1.3) 1.4 (0.9–2.9)` 0.2 (0.2–0.9) 0.6 (0.3–1.4)
Lymphocytes (6103/mg) 0.1 (0.0–0.2) 0.1 (0.1–0.2) 0.0 (0.0–0.0) 0.1 (0.0–0.1)*
Data are presented as median (IQR).
*p,0.05 v smokers; p,0.01 v never smokers; `p,0.05 v former smokers; 1p,0.05 v never smokers; p,0.01 v smokers.
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Importantly, MMP-12 levels were not only increased in
COPD patients who were active smokers but also in those
who had quit smoking. These data suggest that MMP-12 in
sputum is not induced by cigarette smoking per se, but by the
disease itself. However, while there was no statistically
significant difference between COPD patients who had quit
smoking and those who were current smokers, the mean
MMP-12 levels were higher in the latter group which
suggests an additional effect of cigarette smoking on MMP-
12 levels in induced sputum from patients with COPD. It is
important to remember that only patients with mild to
moderate COPD were included in this study; patients with
severe and very severe COPD (GOLD stage III and IV) were
excluded for safety reasons. Thus, in those patients with early
stages of COPD, MMP-12 could be an important biomarker of
the disease. However, there is some overlap between the
lowest MMP-12 levels in COPD patients and the MMP-12
levels in controls. Measurement of MMP-12 in induced
sputum as a screening test for COPD is therefore probably not
useful. However, future studies in larger groups of subjects
are needed to address this question.
The mechanism by which MMP-12 is induced in patients
with COPD remains unclear. Data from animal models
suggest that a local deficiency in transforming growth factor
b1 (TGF-b1)
18 or a rise in interleukin-13 (IL-13)19 or
interferon-c (IFN-c)20 leads to overproduction of macrophage
MMP-12. Grumelli et al21 recently showed that, in human
subjects, lung macrophages release MMP-12 in response to
interferon inducible protein 10 (IP-10) and monokine
induced by interferon (MIG), two chemokines that are
secreted by lung macrophages and lymphocytes from patients
with emphysema.
Alveolar macrophages appear to be the principal source of
MMP-12 in the lung.9 13 However, recent data from in vitro
studies suggest that MMP-12 can also be released by human
bronchial epithelial cells in response to cigarette smoke.22 23
Moreover, in vitro studies show a strong upregulation of
MMP-12 transcription in immature monocyte derived dendri-
tic cells (DC) during differentiation from monocytes into DC.24
So, whereas macrophages are probably the most important
source of MMP-12, both bronchial epithelial cells and DC





























Figure 4 Elevated levels of MMP-12 protein in induced sputum from
COPD patients (n = 28) compared with never smokers (n = 20), healthy































Figure 5 Detection of functionally active MMP-12 by casein
zymography. (A) Functionally active MMP-12 was present in sputum
samples from four of five COPD patients (lanes 1–5), while no
functionally active MMP-12 was detected in sputum from healthy
smokers (lanes 6 and 7). (B) Relative enzymatic activity was highest in
patients with COPD. Data shown are representative of 12 subjects (seven
COPD patients, five healthy smokers). Black bars represent COPD







































Figure 6 Relation between MMP-12 protein levels in induced sputum
and (A) FEV1/FVC ratio and (B) FEV1 (% predicted). A significant inverse
correlation was found for both FEV1/FVC ratio (rs =20.44,
p = 0.00007) and FEV1 % predicted (rs =20.38, p = 0.0008) for all
subjects. &, COPD patients (n = 28); #, controls (healthy smokers, never
smokers, former smokers; n = 48).
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lung. In induced sputum, MMP-12 levels did not correlate with
the absolute number of macrophages. However, as already
suggested by other authors,4 it is probably macrophage
activation rather than the macrophage number that accounts
for the increased total secretion of MMP-12.
Only a few data are available on the role of MMP-12 in
COPD in human subjects. Montan˜o and colleagues25 studied
MMP activity and expression in alveolar macrophages from
patients with COPD; they found increased macrophage
elastolytic activity in COPD patients and suggest that this
enzymatic activity corresponds to MMP-12. Recent work
from Molet and colleagues13 demonstrated enhanced MMP-
12 expression in BAL fluid and in bronchial biopsies from
COPD patients compared with controls (a heterogeneous
group of smokers and non-smokers). As mentioned earlier,
Grumelli et al showed that IP-10 and MIG, released by lung
lymphocytes, upregulated MMP-12 secretion by lung macro-
phages and that this is mediated by the CXCR3 chemokine
receptor on macrophages. Moreover, they showed by immu-
nohistochemistry that lung macrophages from patients with
emphysema express MMP-12 while lung macrophages from
healthy smokers (without emphysema) do not.21
Our results show, for the first time, increased MMP-12
protein levels and MMP-12 related enzymatic activity in
induced sputum from patients with COPD compared with
smokers without obstructive airway disease, former smokers
and never smokers. Altogether, these data provide increasing
evidence that MMP-12 is involved in the development of
COPD in human subjects, and thus confirm the earlier
findings from animal models. It is also clear that MMP-12
could be an interesting target for new pharmacological
treatments for COPD. In mice, a potent synthetic inhibitor
of both human and murine MMP-12 (RS-113456) prevented
progression of emphysema in smoke exposed animals.26
These promising preclinical results, however, need to be
confirmed in well designed clinical trials in human patients.
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Figure 7 Relation between MMP-12 protein levels and absolute
neutrophil number in induced sputum. A significant positive correlation
(rs = 0.41, p = 0.0004) was found between the absolute neutrophil
number and MMP-12 in induced sputum for all subjects. &, COPD
patients (n = 28); #, controls (healthy smokers, never smokers, former
smokers; n = 48).
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